It is also known that adequate radiotherapy can enhance anti-tumor immune responses through immunogenic cell death (ICD) via the release of damage-associated molecular patterns and exposure of MHC Class I and calreticulin [2–4]. This evidence concerns the gene CALR and neoplasm.